Home / Appointment  / Fischer Medical Ventures Appoints Tay Chin Kwang as Group Director of Finance, Chairman Office

Fischer Medical Ventures Appoints Tay Chin Kwang as Group Director of Finance, Chairman Office

MedTech leader strengthens leadership team to drive growth, governance and international expansion Fischer Medical Ventures Limited (FMVL), listed on the BSE (Scrip Code: 524743) and the NSE (Symbol: FISCHER), has announced the appointment of Mr. Tay

Mr. Tay Chin Kwang Group Director of Finance Chairman Office Fischer Medical Ventures Limited

MedTech leader strengthens leadership team to drive growth, governance and international expansion

Fischer Medical Ventures Limited (FMVL), listed on the BSE (Scrip Code: 524743) and the NSE (Symbol: FISCHER), has announced the appointment of Mr. Tay Chin Kwang as Group Director of Finance, Chairman Office. The appointment strengthens the Company’s leadership team as Fischer Medical Ventures advances its long-term strategy for growth, governance and international expansion.

Tay Chin Kwang Brings Two Decades of Finance Leadership Experience

Chin Kwang is a seasoned finance leader with more than two decades of experience across listed companies, high-growth ventures and advisory environments in Singapore and Southeast Asia. He brings extensive expertise in strategic finance, fundraising, investor relations, mergers and acquisitions, corporate restructuring, governance and finance transformation.

Throughout his career, Chin Kwang has worked closely with boards of directors, investors, executive leadership and key stakeholders, leading finance strategy, capital raising initiatives, regional operations and cross-border expansion. His experience includes serving as Chief Financial Officer of various companies listed on the Singapore stock exchange, as well as advising businesses on fundraising, IPO readiness, strategic partnerships and restructuring. He has also supported fundraising initiatives for a China-based life sciences company focused on cancer treatment.

New Role at Fischer Medical Ventures: Strengthening Financial Strategy and Governance

In his new role, Chin Kwang will work closely with the Chairman’s Office to strengthen the Group’s financial strategy, corporate governance, investor engagement and strategic growth initiatives while supporting Fischer Medical Ventures’ expanding presence in healthcare, life sciences and technology-driven businesses.

Leadership Statements on the Appointment

Mr. Ravindran Govindan, Chairman, Fischer Medical Ventures Limited, said:

“We are delighted to welcome Mr. Tay Chin Kwang to Fischer Medical Ventures Limited. His extensive experience in strategic finance, investor relations, fundraising and corporate governance will be invaluable as we continue to strengthen our business and pursue new growth opportunities. His leadership will further enhance our financial discipline, strategic execution and long-term value creation for all stakeholders.”

Mr. Tay Chin Kwang, Group Director of Finance, Chairman Office, Fischer Medical Ventures Limited, said:

“I am honoured to join Fischer Medical Ventures Limited at an exciting stage of its growth journey. The Company has a clear vision to build a strong healthcare and life sciences platform, and I look forward to working closely with the Chairman, Board and management team to strengthen the Group’s financial strategy, support sustainable growth and create long-term value for shareholders while advancing its strategic objectives.”

The appointment reflects Fischer Medical Ventures’ continued commitment to strengthening its leadership team with experienced professionals who can support the Company’s long-term growth strategy, enhance corporate governance and drive sustainable value creation for shareholders.

About Fischer Medical Ventures Limited (BSE: 524743, NSE: FISCHER)

Fischer Medical Ventures Limited (FMVL, the “Company”) is headquartered in Andhra Pradesh, with a facility at the Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam. Its subsidiary, Time Medical International Ventures (India) Private Limited (TMIVPL), is the first Indian company recognized by CDSCO for indigenously manufacturing MRI systems.

FMVL focuses on medical diagnostics, digital health, and AI-powered healthcare software. Its product range includes MRI systems (0.35T & 1.5T), preventive health kiosks, e-health access points (E-HAPs), AI-based software for cancer and TB screening, handheld X-ray devices, SpinCare technology, nutraceuticals from plant extracts, and contactless mental health screening. Upcoming products include oncology and CT scan solutions.

FMVL aims to make healthcare accessible and affordable through innovation and data-driven solutions. Its wholly owned subsidiary, FlynnCare Health Innovations Pvt. Ltd., provides digital platforms for community health screening and hospital connectivity.

 

medgatetoday@gmail.com

Review overview
NO COMMENTS

POST A COMMENT

This site uses Akismet to reduce spam. Learn how your comment data is processed.